This article serves as a STAT news hub covering Amgen Inc., featuring a collection of headlines regarding the company's business and clinical pipeline. It specifically highlights Amgen's position in the competitive GLP-1 weight loss drug market, referencing their candidate MariTide (AMG 133). The coverage notes clinical trial outcomes, including high discontinuation rates in mid-stage studies and subsequent dosing adjustments.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.